Ranbaxy recalls nearly 30,000 packs of allergy-relief drug in U.S
MUMBAI (Reuters) - Drugmaker Ranbaxy Laboratories Ltd (RANB.NS) started recalling 29,790 packs of an allergy-relief medicine in the United States in February, after finding defects in the packaging, the U.S. Food and Drug Administration said.
The loratadine and pseudoephedrine sulphate extended release tablets being recalled carry an expiry date of September 2015, and were manufactured by Ranbaxy's Ohm Labs plant in New Jersey, which is the company's only facility making generics for the United States.
All other Ranbaxy plants, based in India, have been banned from exporting generics to the United States after the FDA found manufacturing quality glitches that the agency believed could compromise the quality of medicines.
Rival Indian drugmaker Sun Pharmaceutical Industries Ltd (SUN.NS) agreed to buy Ranbaxy last month in a $3.2 billion deal, betting it can fix Ranbaxy's problems.
The FDA classified the recall by Ohm Labs as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.
Ranbaxy did not immediately respond to requests for comment.
(Reporting by Zeba Siddiqui in MUMBAI; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- Fears for tough penalties grow as India cleans up business
- India warns Pakistan of more pain in Kashmir fighting
- No fear of deflation: Indian consumers respond to softer oil, food prices
- Giving pricey hepatitis drug to prisoners may be financially wise
- New Jerusalem find may shed light on Jewish revolt against Romans
India's biggest listed property company on Wednesday appealed for interim relief from a three-year ban from accessing capital markets by the regulator. Full Article